MNG524
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.422
- DNA_REPAIR+0.323
- INTERFERON_GAMMA_RESPONSE+0.315
- INTERFERON_ALPHA_RESPONSE+0.292
- OXIDATIVE_PHOSPHORYLATION+0.271
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.243
- MYC_TARGETS_V1+0.201
- APICAL_SURFACE+0.180
- PANCREAS_BETA_CELLS+0.178
- MYC_TARGETS_V2+0.174
Top 10 suppressed
- ANGIOGENESIS-0.387
- PROTEIN_SECRETION-0.380
- G2M_CHECKPOINT-0.368
- MITOTIC_SPINDLE-0.365
- ANDROGEN_RESPONSE-0.319
- E2F_TARGETS-0.316
- HEDGEHOG_SIGNALING-0.299
- MTORC1_SIGNALING-0.282
- TNFA_SIGNALING_VIA_NFKB-0.256
- ESTROGEN_RESPONSE_EARLY-0.223
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG433 | — | — | 0.796 |
| 2 | TCGA-CV-A45T-01A-11R-A24H-07 | — | — | 0.762 |
| 3 | MNG580 | — | — | 0.750 |
| 4 | MNG930 | — | — | 0.742 |
| 5 | MNG1097 | — | — | 0.735 |
| 6 | TCGA-LL-A5YN-01A-11R-A28M-07 | — | B | 0.726 |
| 7 | SRR2016951 | — | — | 0.725 |
| 8 | TCGA-64-5778-01A-01R-1628-07 | — | cohortA1 | 0.716 |
| 9 | TCGA-BH-A2L8-01A-11R-A18M-07 | — | A | 0.713 |
| 10 | TCGA-CQ-5333-01A-01R-2403-07 | — | — | 0.712 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.422 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.323 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.315 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.292 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.271 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.243 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.201 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.178 | Cobimetinib | — uncovered |
| MYC_TARGETS_V2 | 0.174 | Idelalisib | — uncovered |
| PEROXISOME | 0.162 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.144 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| MYOGENESIS | 0.119 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.113 | Idelalisib | — uncovered |
| COMPLEMENT | 0.080 | Inavolisib | — uncovered |
| COAGULATION | 0.073 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.059 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.051 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.046 | Inavolisib | — uncovered |